Levothyroxine BE [Design Issues]

posted by drcampos  – Brazil, 2007-07-19 23:56 (6566 d 00:35 ago) – Posting: # 913
Views: 8,652

Dear All,

Could someone provide information (articles) about linear pharmacokinetics of strenghts of levothyroxine sodium (25, 50, 75, 88, 100, 112, 125, 137, 150, 200 and 300 ug).

I intend to develop a BE study with the highest strength and ask for biowaiver to the lowest strenghts, because a dose of 600ug (2x 300ug) should be given to detect T4 above baseline levels according FDA Guidance (Levothyroxine Sodium Tablets — In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing - 2000).

Regards,

Daniel Rossi de Campos
Brazil

--
Edit: moved to previous thread. [HS]

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,673 registered users;
42 visitors (0 registered, 42 guests [including 11 identified bots]).
Forum time: 00:31 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5